Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Regeneron Pharmaceuticals Inc (REGN)

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia 4/24/2026 10:34:13 AM

Regeneron Pharma: FDA Grants Approval For Otarmeni, Gene Therapy For Genetic Hearing Loss 4/24/2026 12:11:03 AM

FDA Approves First-Ever Gene Therapy For Treatment Of Genetic Hearing Loss 4/23/2026 11:11:34 PM

Sanofi: FDA Approves Dupixent For Young Children With Uncontrolled Chronic Pontaneous Urticaria 4/23/2026 12:36:15 AM

Sanofi : FDA Clears Dupixent As First Biologic For Young Children With Chronic Spontaneous Urticaria 4/22/2026 11:43:07 PM

Regeneron Reports Positive Phase 3 Data For Cemdisiran In Myasthenia Gravis 4/21/2026 1:55:11 PM

Regeneron : Phase 3 Trial Of Cemdisiran Shows Sustained GMG Control With 12-Week Subcutaneous Dosing 4/21/2026 10:41:01 AM

Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study 4/19/2026 12:10:03 AM

Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials 4/17/2026 10:38:28 AM

Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies 4/13/2026 6:54:45 AM

Telix Partners With Regeneron To Develop Radiopharmaceutical Therapies 4/13/2026 6:37:28 AM

Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU 4/13/2026 6:05:47 AM

Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU 4/13/2026 1:34:44 AM

Sanofi, Regeneron: EC Approves Dupixent For Pediatric Chronic Spontaneous Urticaria 4/13/2026 1:09:12 AM

Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies 4/12/2026 11:28:52 PM

Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO 4/10/2026 10:00:43 AM

Regeneron Partners With TriNetX For Access To 300 Million De-Identified Electronic Health Records 4/6/2026 6:30:22 AM

FDA Approves Dosing Interval Extension Up To 20 Weeks For EYLEA HD In WAMD And DME 4/6/2026 4:54:12 AM

Biotech Stocks Facing FDA Decision In April 2026 3/30/2026 6:14:27 AM

Sanofi: MHLW In Japan Approves Dupixent To Treat Moderate-to-severe Bullous Pemphigoid 3/24/2026 2:30:42 AM

- 1
- 2
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap